CSIMarket
 


Trinity Biotech Plc  (TRIB)
Other Ticker:  
 
 

TRIB's Capital Expenditures Growth by Quarter and Year

Trinity Biotech Plc's Capital Expenditures results by quarter and year




TRIB Capital Expenditures (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December 1.10 1.04 3.03 0.00
III Quarter September 0.00 0.58 0.00 0.00
II Quarter June 0.00 0.19 0.17 0.00
I Quarter March 0.00 0.00 0.02 0.06
FY   1.10 1.81 3.22 0.06



TRIB Capital Expenditures fourth quarter 2022 Y/Y Growth Comment
Trinity Biotech Plc reported Capital Expenditures growth of 5.87% year on year in the fourth quarter 2022, to $ 1.10 millions, this is lower than Trinity Biotech Plc's recent average Capital Expenditures surge of 10033.69%.

Looking into fourth quarter 2022 results within In Vitro & In Vivo Diagnostic Substances industry 11 other companies have achieved higher Capital Expenditures growth. While Trinity Biotech Plc' s Capital Expenditures increase of 5.87% ranks overall at the positon no. 1841 in the fourth quarter 2022.




TRIB Capital Expenditures ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December 5.87 % -65.68 % - -
III Quarter September - - - -
II Quarter June - 11.76 % - -
I Quarter March - - -66.67 % -
FY   -39.17 % -43.79 % 5266.67 % 0 %

Financial Statements
Trinity Biotech Plc's fourth quarter 2022 Capital Expenditures $ 1.10 millions TRIB's Income Statement
Trinity Biotech Plc's fourth quarter 2021 Capital Expenditures $ 1.04 millions Quarterly TRIB's Income Statement
New: More TRIB's historic Capital Expenditures Growth >>


TRIB Capital Expenditures (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - 79.31 % - -
III Quarter September - 205.26 % - -
II Quarter June - - 750 % -
I Quarter March - - - -
FY (Year on Year)   -39.17 % -43.79 % 5266.67 % 0 %




Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #323
Overall #1841

Capital Expenditures Y/Y Growth Statistics
High Average Low
90819.91 % 10033.69 % -100 %
(Dec 31 2020)   0
Capital Expenditures fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #12
Healthcare Sector #323
Overall #1841
Capital Expenditures Y/Y Growth Statistics
High Average Low
90819.91 % 10033.69 % -100 %
(Dec 31 2020)   0

Capital Expenditures by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Trinity Biotech Plc's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TRIB's IV. Quarter Q/Q Capital Expenditures Comment


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Capital Expenditures Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TRIB's IV. Quarter Q/Q Capital Expenditures Comment


Trinity Biotech Plc's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 0.00 $ 0.00 $ 1.04 $ 3.76 $ 3.35
Y / Y Capital Expenditures Growth (TTM) - - -65.65 % 2153.48 % -
Year on Year Capital Expenditures Growth Overall Ranking # 3 # 0 # 0 # 0 # 3
Seqeuential Capital Expenditures Change (TTM) - - - 12.11 % 5.43 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1635 # 0 # 0 # 0 # 1921




Cumulative Capital Expenditures growth Comment
In the Dec 31 2022 period, Trinity Biotech Plc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Trinity Biotech Plc achieved highest trailing twelve month year on year Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 3.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
90819.91 %
30969.25 %
-65.65 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
90819.91 %
30969.25 %
-65.65 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 239
S&P 500 # 1635
Cumulative Capital Expenditures growth Comment
In the Dec 31 2022 period, Trinity Biotech Plc's cumulative trailing twelve month Capital Expenditures remained unchanged compare to the same period a year ago.

Trinity Biotech Plc achieved highest trailing twelve month year on year Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 0 to 3.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
90819.91 %
30969.25 %
-65.65 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 0
Overall # 3

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
90819.91 %
30969.25 %
-65.65 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 239
S&P 500 # 1635




Other Capital Expenditures Growth
In Vitro & In Vivo Diagnostic Substances Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
TRIB's Capital Expenditures Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for TRIB's Competitors
Capital Expenditures Growth for Trinity Biotech Plc's Suppliers
Capital Expenditures Growth for TRIB's Customers

You may also want to know
TRIB's Annual Growth Rates TRIB's Profitability Ratios TRIB's Asset Turnover Ratio TRIB's Dividend Growth
TRIB's Roe TRIB's Valuation Ratios TRIB's Financial Strength Ratios TRIB's Dividend Payout Ratio
TRIB's Roa TRIB's Inventory Turnover Ratio TRIB's Growth Rates TRIB's Dividend Comparisons



Companies with similar Capital Expenditures increase for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2022
Infusystem Holdings Inc10.19%$ 10.188 millions
Maravai Lifesciences Holdings Inc 9.75%$ 9.749 millions
Precision Optics Corporation Inc 9.54%$ 9.539 millions
Societal Cdmo Inc 8.40%$ 8.399 millions
9 Meters Biopharma Inc 8.14%$ 8.143 millions
Bristol myers Squibb Company8.13%$ 8.125 millions
Connect Biopharma Holdings Limited7.62%$ 7.618 millions
Casi Pharmaceuticals inc 7.61%$ 7.613 millions
Globus Medical Inc 7.60%$ 7.598 millions
Greenbrook Tms Inc 7.38%$ 7.378 millions
Msa Safety Incorporated7.19%$ 7.193 millions
Organon and Co 6.78%$ 6.780 millions
Heron Therapeutics Inc 6.15%$ 6.154 millions
Trinity Biotech Plc5.86%$ 5.855 millions
Sera Prognostics Inc 5.61%$ 5.607 millions
Bio rad Laboratories Inc 5.36%$ 5.361 millions
Nextcure Inc 4.85%$ 4.848 millions
Avanos Medical Inc 4.26%$ 4.255 millions
Graphite Bio Inc 4.08%$ 4.077 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com